{"id":59842,"date":"2026-03-18T13:52:52","date_gmt":"2026-03-18T05:52:52","guid":{"rendered":"https:\/\/flcube.com\/?p=59842"},"modified":"2026-03-18T13:52:53","modified_gmt":"2026-03-18T05:52:53","slug":"unixell-bio-secures-fda-approval-for-ux-gip001-first-ipsc-allogeneic-cell-therapy-for-epilepsy-enters-us-clinical-trials","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=59842","title":{"rendered":"UniXell Bio Secures FDA Approval for UX\u2011GIP001 \u2013 First iPSC Allogeneic Cell Therapy for Epilepsy Enters US Clinical Trials"},"content":{"rendered":"\n<p><strong>Shanghai UniXell Biotechnology Co., Ltd.<\/strong> announced that its <strong>iPSC\u2011derived allogeneic cell therapy UX\u2011GIP001<\/strong> has received <strong>FDA clinical trial approval<\/strong> in the United States, becoming the <strong>first induced pluripotent stem cell (iPSC)\u2011derived allogeneic cell therapy for epilepsy<\/strong> to enter human clinical development \u2013 a milestone for disease\u2011modifying neuroregenerative medicine.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-regulatory-milestone\">Regulatory Milestone<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Product<\/strong><\/td><td>UX\u2011GIP001<\/td><\/tr><tr><td><strong>Company<\/strong><\/td><td>Shanghai UniXell Biotechnology Co., Ltd.<\/td><\/tr><tr><td><strong>Regulatory Status<\/strong><\/td><td>FDA clinical trial approval (US IND clearance)<\/td><\/tr><tr><td><strong>Therapeutic Class<\/strong><\/td><td>iPSC\u2011derived allogeneic cell therapy<\/td><\/tr><tr><td><strong>Indication<\/strong><\/td><td>Epilepsy<\/td><\/tr><tr><td><strong>Strategic Significance<\/strong><\/td><td><strong>First\u2011in\u2011class<\/strong> \u2013 first iPSC allogeneic cell therapy for epilepsy globally<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-therapeutic-mechanism-amp-innovation\">Therapeutic Mechanism &amp; Innovation<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Cell Source:<\/strong> <strong>iPSC (induced pluripotent stem cell)<\/strong>\u2011derived <strong>allogeneic<\/strong> inhibitory neural progenitor cells<\/li>\n\n\n\n<li><strong>Technology Platform:<\/strong> <strong>Ucytech<\/strong> proprietary human pluripotent stem cell innovation platform<\/li>\n\n\n\n<li><strong>Manufacturing Process:<\/strong><\/li>\n\n\n\n<li><strong>Directed differentiation<\/strong> in vitro simulating neural developmental pathways<\/li>\n\n\n\n<li>Generation of <strong>inhibitory GABAergic interneurons<\/strong> with specific functional characteristics<\/li>\n\n\n\n<li><strong>Mechanism of Action:<\/strong><\/li>\n\n\n\n<li><strong>Direct targeting<\/strong> of impaired GABAergic interneuron function in epileptic brains<\/li>\n\n\n\n<li><strong>Transplantation<\/strong> \u2192 reconstruction of local inhibitory neural circuits<\/li>\n\n\n\n<li><strong>Functional outcome:<\/strong> Reduction of epileptic seizure frequency\/severity<\/li>\n\n\n\n<li><strong>Therapeutic Paradigm Shift:<\/strong><\/li>\n\n\n\n<li><strong>Beyond symptom control:<\/strong> Traditional AEDs (anti\u2011epileptic drugs) modulate neurotransmission without addressing underlying circuit pathology<\/li>\n\n\n\n<li><strong>Disease\u2011modifying potential:<\/strong> Cell therapy aims to restore inhibitory circuit architecture, potentially altering disease trajectory<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-clinical-context-amp-unmet-need\">Clinical Context &amp; Unmet Need<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Dimension<\/th><th>Current Epilepsy Treatment<\/th><th>UX\u2011GIP001 Position<\/th><\/tr><\/thead><tbody><tr><td><strong>Standard of Care<\/strong><\/td><td>Anti\u2011epileptic drugs (AEDs), resective surgery, neuromodulation (VNS, RNS)<\/td><td>Novel cell\u2011based regenerative approach for drug\u2011resistant epilepsy<\/td><\/tr><tr><td><strong>Drug\u2011Resistant Epilepsy<\/strong><\/td><td>~30% of patients fail \u22652 AED trials; limited options beyond invasive surgery<\/td><td>Potential non\u2011resective alternative for focal epilepsy with identified GABAergic deficits<\/td><\/tr><tr><td><strong>Limitations of Existing Therapies<\/strong><\/td><td>Symptom suppression only; no disease modification; cognitive\/mood side effects<\/td><td>Targeted circuit reconstruction; potential for functional cure vs. chronic management<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-impact-amp-outlook\">Market Impact &amp; Outlook<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Epilepsy Market Dynamics:<\/strong> Global epilepsy therapeutics market exceeds <strong>US$20 billion<\/strong> annually; drug\u2011resistant segment (~3 million US patients) drives highest unmet need and healthcare cost burden (surgery, emergency care, lost productivity).<\/li>\n\n\n\n<li><strong>iPSC Cell Therapy Frontier:<\/strong> UX\u2011GIP001 joins limited pipeline of iPSC\u2011derived neural cell therapies (Fate Therapeutics&#8217; iPSC NK cells, BlueRock Therapeutics&#8217; iPSC dopaminergic neurons for Parkinson&#8217;s); first\u2011mover advantage in epilepsy creates platform validation and partnership optionality.<\/li>\n\n\n\n<li><strong>Allogeneic Manufacturing Advantage:<\/strong> &#8220;Off\u2011the\u2011shelf&#8221; iPSC\u2011derived cells vs. autologous approaches enable scalable manufacturing, reduced cost\u2011of\u2011goods, and repeatable dosing \u2013 critical for chronic neurological indications requiring multiple administrations.<\/li>\n\n\n\n<li><strong>Clinical Development Trajectory:<\/strong> Phase I safety\/tolerability data expected 2027\u20112028; efficacy signals in drug\u2011resistant focal epilepsy patients may qualify for <strong>Regenerative Medicine Advanced Therapy (RMAT)<\/strong> designation and accelerated approval pathways.<\/li>\n\n\n\n<li><strong>Strategic Value:<\/strong> UniXell&#8217;s Ucytech platform supports pipeline expansion into other GABAergic circuit disorders (schizophrenia, autism spectrum disorder, anxiety); UX\u2011GIP001 proof\u2011of\u2011concept validates iPSC neural differentiation capabilities for CNS regenerative medicine.<\/li>\n<\/ul>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding clinical development timelines, therapeutic potential, and market expectations for UX\u2011GIP001. Actual results may differ due to risks including safety findings, manufacturing scale\u2011up challenges, and regulatory requirements for novel cell therapy modalities.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Shanghai UniXell Biotechnology Co., Ltd. announced that its iPSC\u2011derived allogeneic cell therapy UX\u2011GIP001 has received&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[62,833],"class_list":["post-59842","post","type-post","status-publish","format-standard","hentry","category-company","category-drug","tag-clinical-trial-approval-initiation","tag-unixell-biotechnology"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>UniXell Bio Secures FDA Approval for UX\u2011GIP001 \u2013 First iPSC Allogeneic Cell Therapy for Epilepsy Enters US Clinical Trials - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Shanghai UniXell Biotechnology Co., Ltd. announced that its iPSC\u2011derived allogeneic cell therapy UX\u2011GIP001 has received FDA clinical trial approval in the United States, becoming the first induced pluripotent stem cell (iPSC)\u2011derived allogeneic cell therapy for epilepsy to enter human clinical development \u2013 a milestone for disease\u2011modifying neuroregenerative medicine.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=59842\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"UniXell Bio Secures FDA Approval for UX\u2011GIP001 \u2013 First iPSC Allogeneic Cell Therapy for Epilepsy Enters US Clinical Trials\" \/>\n<meta property=\"og:description\" content=\"Shanghai UniXell Biotechnology Co., Ltd. announced that its iPSC\u2011derived allogeneic cell therapy UX\u2011GIP001 has received FDA clinical trial approval in the United States, becoming the first induced pluripotent stem cell (iPSC)\u2011derived allogeneic cell therapy for epilepsy to enter human clinical development \u2013 a milestone for disease\u2011modifying neuroregenerative medicine.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=59842\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-03-18T05:52:52+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-03-18T05:52:53+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=59842#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=59842\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"UniXell Bio Secures FDA Approval for UX\u2011GIP001 \u2013 First iPSC Allogeneic Cell Therapy for Epilepsy Enters US Clinical Trials\",\"datePublished\":\"2026-03-18T05:52:52+00:00\",\"dateModified\":\"2026-03-18T05:52:53+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=59842\"},\"wordCount\":515,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Clinical trial approval \\\/ initiation\",\"Unixell Biotechnology\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=59842#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=59842\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=59842\",\"name\":\"UniXell Bio Secures FDA Approval for UX\u2011GIP001 \u2013 First iPSC Allogeneic Cell Therapy for Epilepsy Enters US Clinical Trials - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-03-18T05:52:52+00:00\",\"dateModified\":\"2026-03-18T05:52:53+00:00\",\"description\":\"Shanghai UniXell Biotechnology Co., Ltd. announced that its iPSC\u2011derived allogeneic cell therapy UX\u2011GIP001 has received FDA clinical trial approval in the United States, becoming the first induced pluripotent stem cell (iPSC)\u2011derived allogeneic cell therapy for epilepsy to enter human clinical development \u2013 a milestone for disease\u2011modifying neuroregenerative medicine.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=59842#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=59842\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=59842#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"UniXell Bio Secures FDA Approval for UX\u2011GIP001 \u2013 First iPSC Allogeneic Cell Therapy for Epilepsy Enters US Clinical Trials\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"UniXell Bio Secures FDA Approval for UX\u2011GIP001 \u2013 First iPSC Allogeneic Cell Therapy for Epilepsy Enters US Clinical Trials - Insight, China&#039;s Pharmaceutical Industry","description":"Shanghai UniXell Biotechnology Co., Ltd. announced that its iPSC\u2011derived allogeneic cell therapy UX\u2011GIP001 has received FDA clinical trial approval in the United States, becoming the first induced pluripotent stem cell (iPSC)\u2011derived allogeneic cell therapy for epilepsy to enter human clinical development \u2013 a milestone for disease\u2011modifying neuroregenerative medicine.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=59842","og_locale":"en_US","og_type":"article","og_title":"UniXell Bio Secures FDA Approval for UX\u2011GIP001 \u2013 First iPSC Allogeneic Cell Therapy for Epilepsy Enters US Clinical Trials","og_description":"Shanghai UniXell Biotechnology Co., Ltd. announced that its iPSC\u2011derived allogeneic cell therapy UX\u2011GIP001 has received FDA clinical trial approval in the United States, becoming the first induced pluripotent stem cell (iPSC)\u2011derived allogeneic cell therapy for epilepsy to enter human clinical development \u2013 a milestone for disease\u2011modifying neuroregenerative medicine.","og_url":"https:\/\/flcube.com\/?p=59842","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-03-18T05:52:52+00:00","article_modified_time":"2026-03-18T05:52:53+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=59842#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=59842"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"UniXell Bio Secures FDA Approval for UX\u2011GIP001 \u2013 First iPSC Allogeneic Cell Therapy for Epilepsy Enters US Clinical Trials","datePublished":"2026-03-18T05:52:52+00:00","dateModified":"2026-03-18T05:52:53+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=59842"},"wordCount":515,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Clinical trial approval \/ initiation","Unixell Biotechnology"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=59842#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=59842","url":"https:\/\/flcube.com\/?p=59842","name":"UniXell Bio Secures FDA Approval for UX\u2011GIP001 \u2013 First iPSC Allogeneic Cell Therapy for Epilepsy Enters US Clinical Trials - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-03-18T05:52:52+00:00","dateModified":"2026-03-18T05:52:53+00:00","description":"Shanghai UniXell Biotechnology Co., Ltd. announced that its iPSC\u2011derived allogeneic cell therapy UX\u2011GIP001 has received FDA clinical trial approval in the United States, becoming the first induced pluripotent stem cell (iPSC)\u2011derived allogeneic cell therapy for epilepsy to enter human clinical development \u2013 a milestone for disease\u2011modifying neuroregenerative medicine.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=59842#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=59842"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=59842#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"UniXell Bio Secures FDA Approval for UX\u2011GIP001 \u2013 First iPSC Allogeneic Cell Therapy for Epilepsy Enters US Clinical Trials"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/59842","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=59842"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/59842\/revisions"}],"predecessor-version":[{"id":59843,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/59842\/revisions\/59843"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=59842"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=59842"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=59842"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}